Unlocking the Potential of Receptor-Based Approaches in Diabetes Treatment
Diabetes, a common metabolic condition, poses a substantial health burden worldwide. To revolutionize diabetes management, enhance glycemic control, and decrease the risk of complications, recent research has revealed innovative targets and therapeutic options. A thorough examination of modern drugs...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Compuscript Ltd
2025-01-01
|
| Series: | BIO Integration |
| Subjects: | |
| Online Access: | https://www.scienceopen.com/hosted-document?doi=10.15212/bioi-2024-0047 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832581897784393728 |
|---|---|
| author | Mohsina Patwekar Faheem Patwekar J. Pavan Kumar P. Dharani Prasad Nazia Malik A. Venkata Badarinath Prashanth Parupathi Konatham Teja Kumar Reddy Selvaraja Elumalai Zainul Abedeen Ab Samad |
| author_facet | Mohsina Patwekar Faheem Patwekar J. Pavan Kumar P. Dharani Prasad Nazia Malik A. Venkata Badarinath Prashanth Parupathi Konatham Teja Kumar Reddy Selvaraja Elumalai Zainul Abedeen Ab Samad |
| author_sort | Mohsina Patwekar |
| collection | DOAJ |
| description | Diabetes, a common metabolic condition, poses a substantial health burden worldwide. To revolutionize diabetes management, enhance glycemic control, and decrease the risk of complications, recent research has revealed innovative targets and therapeutic options. A thorough examination of modern drugs that target particular receptors and metabolic pathways for glucose and fat metabolism is presented. Recent research has revealed innovative targets and therapeutic options. Liraglutide, a GLP-1 receptor agonist, has been shown to effectively lower glucagon levels and promote weight loss. Empagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor with substantial promise in decreasing blood glucose levels, and providing cardiovascular and renal advantages. Pegbelfermin (BMS-986036), a fibroblast growth factor 21 (FGF21) analogue, is being investigated for its ability to regulate glucose and lipid metabolism, and potentially enhance glycemic control and lipid profiles. Additionally, G-protein-coupled receptor (GPCR) agonists and adenosine monophosphate-activated protein kinase (AMPK) activators are emerging as potential medicines to improve insulin sensitivity, glucose uptake, and insulin signaling pathways. Despite being in early research stages, bile acid receptor agonists and mitochondrial uncouplers have promising potential for modifying lipid and glucose metabolism. The long-acting insulin analogue insulin glargine, which replaces basal insulin, continues to be a cornerstone of advanced diabetes management. In the future, these medications are expected to be improved through the use of combination therapy and personalized, precision medicine. Gene therapies show promise as novel strategies to address genetic defects and provide potential treatments. Additionally, patient monitoring, adherence, and self-management will be greatly aided by the integration of digital health technology, telemedicine, and artificial intelligence (AI), thus leading to better treatment outcomes and patient quality of life. Healthcare professionals, researchers, politicians, and patients working together will pave the way to substantial improvements in the management of metabolic disorders including diabetes. In conclusion, hope for more efficient, individualized, and secure therapies may come from continuing research and breakthroughs in novel diabetes treatment targets. These developments are at the forefront of offering people with diabetes and related metabolic disorders a better and healthier future, by revolutionizing diabetes management. |
| format | Article |
| id | doaj-art-6307535ae59347de845499f04b4f5c61 |
| institution | Kabale University |
| issn | 2712-0082 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Compuscript Ltd |
| record_format | Article |
| series | BIO Integration |
| spelling | doaj-art-6307535ae59347de845499f04b4f5c612025-01-30T08:26:45ZengCompuscript LtdBIO Integration2712-00822025-01-016110.15212/bioi-2024-0047e999Unlocking the Potential of Receptor-Based Approaches in Diabetes TreatmentMohsina Patwekar0Faheem Patwekar1J. Pavan Kumar2P. Dharani Prasad3Nazia Malik4A. Venkata Badarinath5Prashanth Parupathi6Konatham Teja Kumar Reddy7Selvaraja Elumalai8Zainul Abedeen Ab Samad9Luqman College of Pharmacy, Gulbarga, Karnataka, IndiaLuqman College of Pharmacy, Gulbarga, Karnataka, IndiaResearch Scholar, Department of Pharmacy, Raffles University, Neemrana, Alwar, Rajasthan 301705, IndiaDepartment of Pharmacology, Mohan Babu University, MB School of Pharmaceutical Sciences (Erstwhile Sree Vidyanikethan College of Pharmacy), Tirupati, IndiaDepartment of Pharmacy, TRR pharmacy College, Pragathi Colony, Meerpet, Pragathi Colony, Hyderabad, Telangana 500097, IndiaDepartment of Pharmaceutics, Santhiram College of Pharmacy, Andhra Pradesh, IndiaDepartment of Pharmacy Practice, St. Peter’s Institute of Pharmaceutical Sciences, Hanamkonda, Telangana 506331, IndiaDepartment of Pharmacy, University College of Technology, Osmania University, Amberpet, Hyderabad, Telangana 500007, IndiaDepartment of Chemistry, Raffles University, Neemrana, Alwar, Rajasthan 301705, IndiaLuqman College of Pharmacy, Gulbarga, Karnataka, IndiaDiabetes, a common metabolic condition, poses a substantial health burden worldwide. To revolutionize diabetes management, enhance glycemic control, and decrease the risk of complications, recent research has revealed innovative targets and therapeutic options. A thorough examination of modern drugs that target particular receptors and metabolic pathways for glucose and fat metabolism is presented. Recent research has revealed innovative targets and therapeutic options. Liraglutide, a GLP-1 receptor agonist, has been shown to effectively lower glucagon levels and promote weight loss. Empagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor with substantial promise in decreasing blood glucose levels, and providing cardiovascular and renal advantages. Pegbelfermin (BMS-986036), a fibroblast growth factor 21 (FGF21) analogue, is being investigated for its ability to regulate glucose and lipid metabolism, and potentially enhance glycemic control and lipid profiles. Additionally, G-protein-coupled receptor (GPCR) agonists and adenosine monophosphate-activated protein kinase (AMPK) activators are emerging as potential medicines to improve insulin sensitivity, glucose uptake, and insulin signaling pathways. Despite being in early research stages, bile acid receptor agonists and mitochondrial uncouplers have promising potential for modifying lipid and glucose metabolism. The long-acting insulin analogue insulin glargine, which replaces basal insulin, continues to be a cornerstone of advanced diabetes management. In the future, these medications are expected to be improved through the use of combination therapy and personalized, precision medicine. Gene therapies show promise as novel strategies to address genetic defects and provide potential treatments. Additionally, patient monitoring, adherence, and self-management will be greatly aided by the integration of digital health technology, telemedicine, and artificial intelligence (AI), thus leading to better treatment outcomes and patient quality of life. Healthcare professionals, researchers, politicians, and patients working together will pave the way to substantial improvements in the management of metabolic disorders including diabetes. In conclusion, hope for more efficient, individualized, and secure therapies may come from continuing research and breakthroughs in novel diabetes treatment targets. These developments are at the forefront of offering people with diabetes and related metabolic disorders a better and healthier future, by revolutionizing diabetes management.https://www.scienceopen.com/hosted-document?doi=10.15212/bioi-2024-0047diabetesglp-1 agonistsmetabolic disordersreceptorssglt2 inhibitorstherapeutic targets |
| spellingShingle | Mohsina Patwekar Faheem Patwekar J. Pavan Kumar P. Dharani Prasad Nazia Malik A. Venkata Badarinath Prashanth Parupathi Konatham Teja Kumar Reddy Selvaraja Elumalai Zainul Abedeen Ab Samad Unlocking the Potential of Receptor-Based Approaches in Diabetes Treatment BIO Integration diabetes glp-1 agonists metabolic disorders receptors sglt2 inhibitors therapeutic targets |
| title | Unlocking the Potential of Receptor-Based Approaches in Diabetes Treatment |
| title_full | Unlocking the Potential of Receptor-Based Approaches in Diabetes Treatment |
| title_fullStr | Unlocking the Potential of Receptor-Based Approaches in Diabetes Treatment |
| title_full_unstemmed | Unlocking the Potential of Receptor-Based Approaches in Diabetes Treatment |
| title_short | Unlocking the Potential of Receptor-Based Approaches in Diabetes Treatment |
| title_sort | unlocking the potential of receptor based approaches in diabetes treatment |
| topic | diabetes glp-1 agonists metabolic disorders receptors sglt2 inhibitors therapeutic targets |
| url | https://www.scienceopen.com/hosted-document?doi=10.15212/bioi-2024-0047 |
| work_keys_str_mv | AT mohsinapatwekar unlockingthepotentialofreceptorbasedapproachesindiabetestreatment AT faheempatwekar unlockingthepotentialofreceptorbasedapproachesindiabetestreatment AT jpavankumar unlockingthepotentialofreceptorbasedapproachesindiabetestreatment AT pdharaniprasad unlockingthepotentialofreceptorbasedapproachesindiabetestreatment AT naziamalik unlockingthepotentialofreceptorbasedapproachesindiabetestreatment AT avenkatabadarinath unlockingthepotentialofreceptorbasedapproachesindiabetestreatment AT prashanthparupathi unlockingthepotentialofreceptorbasedapproachesindiabetestreatment AT konathamtejakumarreddy unlockingthepotentialofreceptorbasedapproachesindiabetestreatment AT selvarajaelumalai unlockingthepotentialofreceptorbasedapproachesindiabetestreatment AT zainulabedeenabsamad unlockingthepotentialofreceptorbasedapproachesindiabetestreatment |